Myasthenia Gravis, Autoimmune, Experimental
"Myasthenia Gravis, Autoimmune, Experimental" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any autoimmune animal disease model used in the study of MYASTHENIA GRAVIS. Injection with purified neuromuscular junction acetylcholine receptor (AChR) (see RECEPTORS, CHOLINERGIC) components results in a myasthenic syndrome that has acute and chronic phases. The motor endplate pathology, loss of acetylcholine receptors, presence of circulating anti-AChR antibodies, and electrophysiologic changes make this condition virtually identical to human myasthenia gravis. Passive transfer of AChR antibodies or lymphocytes from afflicted animals to normals induces passive transfer experimental autoimmune myasthenia gravis. (From Joynt, Clinical Neurology, 1997, Ch 54, p3)
MeSH Number(s)
C10.114.656.300
C10.114.703.350
C10.668.758.725.300
C20.111.258.500.300
C20.111.258.625.350
E05.598.500.500.750
Concept/Terms
Myasthenia Gravis, Autoimmune, Experimental- Myasthenia Gravis, Autoimmune, Experimental
- Myasthenia Gravis, Experimental Autoimmune
- Experimental Myasthenia Gravis
- Myasthenia Gravis, Experimental
- Autoimmune Experimental Myasthenia Gravis
- Experimental Myasthenia
- Experimental Myasthenias
- Myasthenia, Experimental
- Myasthenias, Experimental
- Myasthenia Gravis, Autoimmune Experimental
Below are MeSH descriptors whose meaning is more general than "Myasthenia Gravis, Autoimmune, Experimental".
- Diseases [C]
- Nervous System Diseases [C10]
- Autoimmune Diseases of the Nervous System [C10.114]
- Myasthenia Gravis [C10.114.656]
- Myasthenia Gravis, Autoimmune, Experimental [C10.114.656.300]
- Nervous System Autoimmune Disease, Experimental [C10.114.703]
- Myasthenia Gravis, Autoimmune, Experimental [C10.114.703.350]
- Neuromuscular Diseases [C10.668]
- Neuromuscular Junction Diseases [C10.668.758]
- Myasthenia Gravis [C10.668.758.725]
- Myasthenia Gravis, Autoimmune, Experimental [C10.668.758.725.300]
- Immune System Diseases [C20]
- Autoimmune Diseases [C20.111]
- Autoimmune Diseases of the Nervous System [C20.111.258]
- Myasthenia Gravis [C20.111.258.500]
- Myasthenia Gravis, Autoimmune, Experimental [C20.111.258.500.300]
- Nervous System Autoimmune Disease, Experimental [C20.111.258.625]
- Myasthenia Gravis, Autoimmune, Experimental [C20.111.258.625.350]
- Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
- Investigative Techniques [E05]
- Models, Animal [E05.598]
- Disease Models, Animal [E05.598.500]
- Nervous System Autoimmune Disease, Experimental [E05.598.500.500]
- Myasthenia Gravis, Autoimmune, Experimental [E05.598.500.500.750]
Below are MeSH descriptors whose meaning is more specific than "Myasthenia Gravis, Autoimmune, Experimental".
This graph shows the total number of publications written about "Myasthenia Gravis, Autoimmune, Experimental" by people in Harvard Catalyst Profiles by year, and whether "Myasthenia Gravis, Autoimmune, Experimental" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2012 | 2 | 0 | 2 |
| 2018 | 1 | 0 | 1 |
Below are the most recent publications written about "Myasthenia Gravis, Autoimmune, Experimental" by people in Profiles.
-
A Natural Variant of the Signaling Molecule Vav1 Enhances Susceptibility to Myasthenia Gravis and Influences the T Cell Receptor Repertoire. Front Immunol. 2018; 9:2399.
-
Cell surface complement regulators moderate experimental myasthenia gravis pathology. Muscle Nerve. 2013 Jan; 47(1):33-40.
-
DAF/CD55 and Protectin/CD59 modulate adaptive immunity and disease outcome in experimental autoimmune myasthenia gravis. J Neuroimmunol. 2012 Mar; 244(1-2):63-9.
-
Activation of the receptor for advanced glycation end products (RAGE) exacerbates experimental autoimmune myasthenia gravis symptoms. Clin Immunol. 2011 Oct; 141(1):36-48.
-
CCL2 recruitment of IL-6-producing CD11b+ monocytes to the draining lymph nodes during the initiation of Th17-dependent B cell-mediated autoimmunity. Eur J Immunol. 2008 Jul; 38(7):1877-88.
-
A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis. J Neuroimmunol. 2008 Feb; 194(1-2):89-96.
-
Suppression of experimental autoimmune myasthenia gravis by intravenous immunoglobulin and isolation of a disease-specific IgG fraction. Ann N Y Acad Sci. 2007 Sep; 1110:550-8.
-
Experimental autoimmune myasthenia gravis in naive non-obese diabetic (NOD/LtJ) mice: susceptibility associated with natural IgG antibodies to the acetylcholine receptor. Int Immunol. 2003 Jan; 15(1):11-6.